Advancing medicines for solid tumors

Context is dedicated to developing the next generation of therapies to treat solid tumors. We are advancing the bispecific antibody (CTIM-76), an investigational anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAbs) intended to redirect T-cell mediated lysis toward malignant cells expressing CLDN6.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Events